N/A N=40 Surgical Theater's Surgery Rehearsal Platform
Cerebral Aneurysm Unruptured · Cerebral Aneurysm Ruptured
Primary: Aneurysm Clip Time
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=12 Dose-Titration and Open-label Extension Study of SRP-4045 in Advanced Stage Duchenne Muscular Dystrophy (DMD) Patients
Duchenne Muscular Dystrophy
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 4; 5; 3; 3 Participants
Phase 2 N=12 Phase I/II Study of SRP-4053 in DMD Patients
Duchenne Muscular Dystrophy
Primary: Part 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs and TEAEs Leading to Discontinuation — 4; 5; 5; 3 Participants
N/A N=345 SPARK Symptom Screening and Feedback to Providers
Pediatric Oncology · Quality of Life
Primary: SSPedi (Symptom Screening in Pediatrics) Total Scores — 13.2; 13.1; 10.2; 12.7 score on a scale
N/A N=941 Sertraline Pediatric Registry for the Evaluation of Safety (SPRITES)
Obsessive Compulsive Disorder
Primary: Change From Baseline in Cognitive Function Using Trails B at Month 3 — 1.03; 1.23; 0.61; -0.39 Z-score
N/A N=504 Protecta Smart Analysis Register
Patients With an Indication for an ICD Implantation According to the Guidelines
Primary: Analysis of Change of Episodes Inappropriately Treated by Shock Therapy Due to Smart Shock™ Technology. — 94.9 % of episodes wo shock due to SmartShock
Phase 2 N=6 A Gene Transfer Therapy Study to Evaluate the Safety of SRP-9004 (Patidistrogene Bexoparvovec) in Participants With Limb-Girdle Muscular Dystrophy, Type 2D (LGMD2D)
Limb-Girdle Muscular Dystrophy, Type 2D
Primary: Number of Participants With Adverse Events (AEs). — 1; 3; 2; 0 Participants
N/A N=128 SPYRAL DYSTAL Renal Denervation Global Clinical Study
Hypertension · Vascular Diseases · Cardiovascular Diseases
Primary: Change in Systolic Blood Pressure (SBP) as Measured by 24-hour Ambulatory Blood Pressure Monitoring (ABPM) — -16.6 mmHg
Phase 4 N=609 STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction
Myocardial Infarction
Primary: Successful Reperfusion — 305; 149 Participants — p=0.05
N/A N=56 Enhanced Recovery After Spine Surgery
Enhanced Recovery After Surgery · Spine Surgery
Primary: Patient Score on QoR40 Inventory. — 179.4; 170.3 scores on a scale
Phase 4 N=52 XRB vs. SLB in Jail and at Re-entry: Pilot, Proof of Concept
Opioid Dependence
Primary: # of Participants Retained on Any Form of Community Buprenorphine (Not Randomzied tx) at Week 8 — 18; 9 Participants
N/A N=502 Zithromax-SR 2g, Special Investigation (Regulatory Post Marketing Commitment Plan)
Bacterial Infections
Primary: Number of Participants With an Investigator's Assessment of Clinical Outcome (Effective (Cured)/ Not Effective (Not Cured)) at End of the Study. — 438; 19 participants
Phase 3 N=3,395 Recommendations of Enhanced Recovery Interventions for Patient's Clinical Team and Collection of Associated Data
Perioperative Optimization
Primary: 30 Day Hospital Free Days — 27; 27; 26; 27 Number of hospital free days
N/A N=77 SCP Hip Outcomes Study
Subchondral Cysts · Subchondral Bone Edema · Bone Marrow Edema
Primary: Overall Group Mean Improvement From Baseline of the Modified Harris Hip Score (mHHS) at 2 Years — 25.8; 26.3; 24.8 score on a scale
N/A N=172 Systematic Multi-domain Alzheimer's Risk Reduction Trial
Dementia · Alzheimer Disease
Primary: Cognitive Change — 0.34; 0.19 z-score — p=0.008
Phase 2 N=58 An Active Treatment Study of SRK-015 in Patients With Type 2 or Type 3 Spinal Muscular Atrophy
Spinal Muscular Atrophy · Spinal Muscular Atrophy Type 3 · Spinal Muscular Atrophy Type 2
Primary: Cohort 1: Change From Baseline in the Revised Hammersmith Scale (RHS) Total Score at Day 364 (Visit 15) [Month 12] — -0.1; 0.0 score on a scale
Phase 2 N=14 Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP Study)
Retinopathy of Prematurity
Primary: Efficacy as Measured by the Number of Participants Presenting With Retinopathy of Prematurity (ROP) and the Rate of Stages/Grade of ROP. — 5; 3; 4; 1 Participants
N/A N=21 SRL (Sirolimus) Withdrawal
Acute Rejection of Liver Transplant · Effects of Immunosuppressant Therapy
Primary: Proportion of Tolerant Patients Off SRL Therapy With Normal Liver Biochemistry and Graft Histology at 12 Months — 8 Participants
Phase 2 N=40 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPARC1316
Asthma
Primary: Number of Subjects With Adverse Events — 0; 0; 0; 0 participants
Phase 2 N=45 Gene Therapy for X-linked Retinitis Pigmentosa (XLRP) - Retinitis Pigmentosa GTPase Regulator (RPGR)
X-Linked Retinitis Pigmentosa
Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 9 Weeks Following Administration, at Least Possibly Related to…
Phase 3 N=240 Comparison of Bimatoprost Sustained Release (SR) to Selective Laser Trabeculoplasty (SLT) in Adults With Open-Angle Glaucoma or Ocular Hypertension
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Change From Baseline in Intraocular Pressure at Week 4 — -6.2; -6.8 mmHg — p=0.0231
Phase 2 N=50 A Dose Response Study of UT-15C SR in Patients With Exercise-Induced Pulmonary Hypertension
Pulmonary Hypertension
Primary: Change in Peak Total Pulmonary Resistance Index (TPRI) During Exercise From Baseline to Week 12 — 15.096; 13.954; 15.441; 14.608 mmHg/(L/min/m^2) — p=0.95
Phase 2 N=25 Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus
Super-refractory Status Epilepticus
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 17; 6 Participants
N/A N=18,693 Paediatric Rapid Sepsis Trigger (PRST) Tool
Sepsis · Infection
Primary: Time to Administration of an Appropriate Antimicrobial — 115; 123; 239; 261 minutes
N/A N=9 (SBRT) and (ART) for Pulmonary Metastases From Soft Tissue Sarcomas
Stage IV Adult Soft Tissue Sarcoma · Sarcoma,Soft Tissue
Primary: Number of Adverse Events of Grade ≥ 3 by CTCAE Criteria. — 8 events
Phase 3 N=85 GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia, in Relapse
Primary: Duration of Asparaginase Activity >100 U/L During Induction — 18.9; 8.5 days
N/A N=381 Medtronic Signia SDR Product Surveillance Registry
Minimally Invasive Surgical Procedures · Surgical Procedures, Operative
Primary: Incidence of Intraoperative Hemostatic Intervention — 3; 2; 0 Firings
N/A N=314 Spaeth/Richman Contrast Sensitivity Test
Glaucoma
Primary: Contrast Sensitivity, Another Means of Testing Vision — 59.4; 74.4; 53.9 units on a scale
N/A N=1,197 Electronic Patient Reporting of Symptoms During Cancer Treatment
Metastatic Cancer
Primary: Overall Survival — 42.0; 43.5 percentage of participants
N/A N=11,288 Leuplin SR 11.25 mg Injection Kit Specified Drug-use Survey "Long-term Use Survey in Prostate Cancer Patients (96 Weeks)"
Prostate Cancer
Primary: Number of Participants Reporting One or More Adverse Drug Reactions — 2052 participants